NIMVASTID 6mg orodispersable tablets medication leaflet

N06DA03 rivastigmine • Nervous system | Anti-dementia drugs | Anticholinesterases

Rivastigmine is a medication used for the symptomatic treatment of mild to moderate dementia associated with Alzheimer’s disease or Parkinson’s disease. It belongs to the class of cholinesterase inhibitors, working by increasing the levels of acetylcholine in the brain, a neurotransmitter essential for memory, learning, and thinking processes.

Rivastigmine is indicated to slow the progression of cognitive symptoms such as memory loss, difficulty concentrating, and reduced ability to perform daily activities. While it does not cure the disease, it can temporarily improve cognitive function and quality of life for patients.

The medication is available in the form of capsules, oral solution, or transdermal patches. The dose is gradually adjusted to minimize side effects, which may include nausea, vomiting, diarrhea, loss of appetite, and dizziness. Transdermal patches are often preferred to reduce the risk of gastrointestinal side effects.

Treatment with rivastigmine should be administered under the supervision of a doctor, and patients should be regularly monitored to assess efficacy and tolerability. Caregivers play an important role in ensuring proper administration and observing for any adverse effects.

General data about NIMVASTID 6mg

Substance: rivastigmine

Date of last drug list: 01-06-2025

Commercial code: W54542001

Concentration: 6mg

Pharmaceutical form: orodispersable tablets

Quantity: 28

Product type: generic

Price: 63.40 RON

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: KRKA ,D.D., NOVO MESTO - SLOVENIA

Holder: KRKA ,D.D., NOVO MESTO - SLOVENIA

Number: 525/2009/01

Shelf life: 2 years

Pharmaceutical forms available for rivastigmine

Concentrations available for rivastigmine

1.5mg, 13.3mg/24h, 2mg/ml, 3.0mg, 3mg, 4.5mg, 4.6mg/24h, 6mg, 9.5mg/24h
PDF icon EMA leaflet
Published: 04/06/2009
Updated: 26/03/2025

Other substances similar to rivastigmine

Compensation lists for NIMVASTID 6mg KRKA

G16 (C1) - Dementia (degenerative, vascular, mixed)

Price

Copayment

Patient

63.40 RON

63.40 RON

0.00 RON

GX (C1) - GENERIC (used in compensation list, C1, for another diagnosis)

Price

Copayment

Patient

63.40 RON

63.40 RON

0.00 RON